Clinical Trials

NCT Number: NCT06067269 Phase: PHASE2 Trial Summary: This phase II trial evaluates apalutamide in combination with image-guided stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate cancer. Prostate cancer usually needs – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Jonsson Comprehensive Cancer Center Acronym: HEATWAVE

NCT Number: NCT06096870 Phase: PHASE2 Trial Summary: Prostate cancer may return after treatment in 30,000 to 50,000 people each year. There is no clear best way to treat these people. Better treatments are needed. Objective: To test a study – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): National Cancer Institute (NCI) Acronym:

NCT Number: NCT06125145 Phase: PHASE2 Trial Summary: The goal of this clinical trial is to test a new way to help older adults who have had cancer. The researchers want to see if a program that assesses participants health and aging is achievable and m – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): […]

NCT Number: NCT05099679 Phase: NA Trial Summary: Pilot study to determine the feasibility of providing psychosocial and cardiac rehabilitation services to address socioeconomic health disparities and improve wellbeing for black m – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Stanford University Acronym:

NCT Number: NCT04927663 Phase: Phase 1 Trial Summary: This phase I trial studies if positron emission tomography (PET) imaging using 11C-YJH08 can be useful for detecting certain cell receptor expression in tumor cells in patients wit – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Rahul Aggarwal Acronym:

NCT Number: NCT05415696 Phase: NA Trial Summary: The purpose of this study is to learn if the prostatic artery embolization procedure can reduce urinary tract symptoms in patients with enlarged prostates and prostate cancer. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Stanford University Acronym:

NCT Number: NCT05652686 Phase: PHASE1|PHASE2 Trial Summary: PT217 is a bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47). This is an open label, Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and prelimin – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Phanes Therapeutics Acronym:

NCT Number: NCT05707182 Phase: EARLY_PHASE1 Trial Summary: The purpose of this study is to investigate the usefulness of PET/MRI with an investigational radioactive drug, 18F-rhPSMA-7.3, and MRI contrast in evaluating patients with prostate cancer eligible fo – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Alabama at Birmingham Acronym:

NCT Number: NCT05726292 Phase: PHASE2 Trial Summary: Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as h – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Chicago Acronym:

NCT Number: NCT05799248 Phase: PHASE3 Trial Summary: Study Title: Role of rhPSMA-7.3 PET/CT imaging in men with High-Risk prostate cancer following conventional imaging and associated changes in medical management Protocol number: BED-IIT-437 Phase: 3b – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): MidLantic Urology Acronym: